ATAC-seq Assay with Low Mitochondrial DNA Contamination from Primary Human CD4+ T Lymphocytes
March 22nd, 2019
12.3K views
Here, we present a protocol to perform an assay for transposase-accessible chromatin sequencing (ATAC-seq) on activated CD4+ human lymphocytes. The protocol has been modified to minimize contaminating mitochondrial DNA reads from 50% to 3% through the introduction of a new lysis buffer.
Overview
This article presents a modified protocol for performing ATAC-seq on activated CD4+ human lymphocytes. The new lysis buffer significantly reduces mitochondrial DNA contamination, enhancing the efficiency of the assay.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Genomics
Background
- ATAC-seq is a technique used to study chromatin accessibility.
- Mitochondrial DNA contamination can skew sequencing results.
- Activated CD4+ T cells are crucial for immune response studies.
- Minimizing sample loss is essential for high-quality ATAC-seq results.
Purpose of Study
- To present a refined ATAC-seq protocol for human lymphocytes.
- To reduce mitochondrial contamination in sequencing data.
- To validate the protocol across various cell types.
Methods Used
- Introduction of a new lysis buffer to minimize contamination.
- Validation of the protocol in human primary PBMCs and monocytes.
- Application of the method to mouse dendritic cells and melanoma cell lines.
- Demonstration of handling small cell numbers from precious samples.
Main Results
- Mitochondrial DNA reads were reduced from 50% to less than 3%.
- The protocol allows for a 50% decrease in sequencing costs.
- Validated effectiveness across multiple cell types.
- Demonstrated handling of small cell samples with basic equipment.
Conclusions
- The modified ATAC-seq protocol enhances data quality.
- It is applicable to a wide range of cell types.
- This approach can facilitate more efficient chromatin accessibility studies.
Frequently Asked Questions
What is ATAC-seq?
ATAC-seq is a method for assessing chromatin accessibility in various cell types.
Why is reducing mitochondrial contamination important?
High mitochondrial contamination can lead to inaccurate sequencing results.
What cell types were validated in this study?
The protocol was validated in human PBMCs, monocytes, mouse dendritic cells, and melanoma cell lines.
How does the new lysis buffer improve the protocol?
It significantly reduces mitochondrial DNA reads, enhancing the quality of the sequencing data.
Can this protocol be used for small sample sizes?
Yes, the protocol is designed to handle small numbers of cells effectively.
What equipment is needed for this protocol?
Basic laboratory equipment is sufficient to perform the protocol.
Executive Industry Relevance
Reducing mitochondrial DNA contamination in ATAC-seq directly improves data quality and cost efficiency in epigenetics research. This advancement supports target validation and mechanistic de-risking in early discovery by providing cleaner chromatin accessibility profiles. The protocol enables reproducible results from limited primary cell samples, enhancing portfolio triage decisions in immunology and oncology programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through high-fidelity chromatin accessibility mapping in primary human CD4+ T lymphocytes.
- Operational Value: Reduces mitochondrial DNA reads from ~50% to 3%, increasing usable sequencing data and lowering per-sample costs.
- Predictive Value: Supports biological de-risking of targets in immune-mediated diseases by delivering reproducible epigenomic profiles across biological replicates.
Screening & Assay Development
- Scientific Value: Produces standardized, high-quality ATAC-seq libraries suitable for downstream screening applications in primary immune cells.
- Operational Value: Utilizes basic laboratory equipment and a streamlined 48-hour workflow, improving assay readiness and scalability.
- Predictive Value: Facilitates reliable compound screening by ensuring consistent chromatin state readouts with minimal technical noise.
Translational & Preclinical Research
- Scientific Value: Demonstrates utility in activated CD4+ T cells, a disease-relevant system for studying immune activation and inflammatory pathways.
- Operational Value: Maintains high reproducibility across technical and biological replicates, supporting assay transfer between discovery and preclinical teams.
- Predictive Value: Enables risk-adjusted advancement decisions by providing quantifiable, epigenetically grounded biomarkers of T cell activation state.
Pipeline & Workflow Integration
The method fits within the early discovery continuum, supporting hypothesis testing in target validation and enabling scalable assay deployment for lead identification efforts in immunology.
- Discovery Biology: Supports mechanistic de-risking by clarifying epigenetic pathways in primary human T cells following activation.
- Screening: Delivers quantitative, nucleosome-resolution chromatin accessibility data with low mitochondrial interference for reliable compound evaluation.
- Analytics: Generates high-confidence peak calls and differential accessibility metrics that inform target engagement and pathway modulation.
- Translational Research: Connects epigenomic changes in activated CD4+ T cells to preclinical models of immune response and inflammation.
- Enterprise Reuse: Establishes a reusable, cost-effective ATAC-seq workflow applicable across primary immune and tumor cell types for sustained discovery programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing epigenomic noise from mitochondrial contamination.
- Operational Value: Cuts sequencing costs by ~50% through improved on-target reads, enhancing throughput in epigenetics screening.
- Strategic Value: Improves go/no-go decisions by delivering higher-quality, reproducible chromatin accessibility data from limited primary samples.
- Portfolio Impact: Enables risk-adjusted prioritization of immunomodulatory targets based on robust, epigenetically informed mechanistic insights.
Implementation Considerations
- Requires expertise in primary immune cell isolation, activation, and epigenetic assay handling.
- Depends on standard laboratory equipment including centrifuges, magnets, thermocyclers, and next-generation sequencers.
- Necessitates standardized reagent preparation and cold-chain lysis buffer handling to maximize nuclei recovery.
- Adaptation to other primary cell types may require optimization of activation and isolation steps while preserving low mitochondrial contamination.
- Practical limitation: Protocol efficiency is tied to careful sample handling during activation and selection to minimize loss of precious primary cells.
Biopharma FAQs
Why does reducing mitochondrial DNA contamination matter for ATAC-seq target validation?
High mitochondrial DNA reads reduce usable sequencing depth and increase cost, obscuring true chromatin accessibility signals. Lowering contamination to 3% improves signal-to-noise ratio, enabling more confident identification of differentially accessible regions in primary human CD4+ T cells. This enhances the reliability of epigenomic data used to validate therapeutic targets in immune pathways.
How does isolating nuclei and using a chilled lysis buffer improve ATAC-seq data quality?
The modified lysis buffer is gentler on cells and performed with chilled reagents to maximize recovery of intact nuclei while minimizing mitochondrial DNA release. This approach reduces contaminating mitochondrial reads from ~50% to 3%, increasing the proportion of nuclear-derived reads. The result is higher-quality libraries with improved reproducibility across biological and technical replicates.
What quantitative measurements enable assessment of ATAC-seq library quality in this protocol?
Library quality is assessed by mitochondrial DNA contamination rate (reduced to 3%), DNA yield (>1 ng/µL), fragment size distribution (200–1,000 bp), and sequencing depth (~42 million reads/sample). These metrics ensure sufficient usable reads for peak calling and differential accessibility analysis. Consistent performance across replicates supports reliable downstream epigenomic comparisons.
Why are replication requirements important for cross-functional collaboration in epigenetics projects?
The protocol demonstrates high reproducibility across technical and biological replicates, ensuring consistent chromatin accessibility profiles. This reliability allows discovery, assay development, and preclinical teams to compare results with confidence. Reproducible data reduces ambiguity in target validation and supports aligned decision-making across functions.
What statistical analysis capabilities are required before implementing this ATAC-seq protocol in a discovery pipeline?
Implementation requires bioinformatics tools for read alignment, peak calling, and differential accessibility analysis (e.g., MACS2, DiffBind or similar). The protocol enables accurate peak prediction and identification of chromatin state changes during T cell activation. Access to sequencing data processing pipelines is essential to derive mechanistic insights from the improved signal quality.
